Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 3/20 | 0.50 |
| ▸ | PARP1 | P09874 | 6/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 7/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.38 |
| ▸ | METAP2 | P50579 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28871452 | 0.97 | TRPA1 (0.48) | TRPA1PARP1CYP11B1CYP11B2METAP2 | |
| SCHEMBL2635508 | 0.85 | TRPA1 (0.39) | TRPA1PARP1KDM4EALDH1A1MAPT | |
| SCHEMBL16058055 | 0.74 | PARP1 (0.41) | TRPA1PARP1CYP11B1CYP11B2METAP2 | |
| SCHEMBL30403098 | 0.71 | CA2 (0.36) | — | |
| SCHEMBL2599647 | 0.70 | ADRA2A (0.38) | — | |
| SCHEMBL30066970 | 0.69 | PARP1 (0.50) | TRPA1PARP1CYP11B1CYP11B2METAP2 | |
| SCHEMBL5322267 | 0.69 | PARP1 (0.50) | TRPA1PARP1CYP11B1CYP11B2METAP2 | |
| SCHEMBL8079405 | 0.69 | PARP1 (0.46) | TRPA1PARP1CYP11B1CYP11B2KDM4E | |
| SCHEMBL13098214 | 0.67 | TRPA1 (1.00) | TRPA1PARP1MAPT | |
| SCHEMBL1720148 | 0.66 | PARP1 (0.54) | TRPA1PARP1CYP11B1CYP11B2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119136809-A | Azasetron for treating sudden acoustic nerve hearing loss | 森索睿翁公司 | 2024-12-13 | — | — | CN | claimed |
| WO-2002036114-A1 | COMPOSITION COMPRISING SEROTONIN RECEPTOR ANTAGONISTS, 5 HT-2 AND 5 HT-3 | RESPIRATORIUS AB (SE) | 2002-05-10 | — | — | WO | claimed |
| WO-2001009127-A1 | BENZOXAZINE DERIVATIVES AND THEIR THERAPEUTIC USE | AVENTIS PHARMA S.A. (FR) | 2001-02-08 | — | — | WO | claimed |
| CN-119136809-A | Azasetron for treating sudden acoustic nerve hearing loss | 森索睿翁公司 | 2024-12-13 | — | — | CN | disclosed |
| US-11278530-B2 | Polycyclic amides as muscarinic M1 receptor positive allosteric modulators | SUVEN LIFE SCIENCES LIMITED (IN) | 2022-03-22 | — | — | US | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| WO-2002036113-A1 | COMPOSITION COMPRISING: SEROTONIN RECEPTOR ANTAGONISTS (5HT-2, 5HT-3) AND AGONIST (5HT-4) | RESPIRATORIUS AB (SE) | 2002-05-10 | — | — | WO | disclosed |
| WO-2002036114-A1 | COMPOSITION COMPRISING SEROTONIN RECEPTOR ANTAGONISTS, 5 HT-2 AND 5 HT-3 | RESPIRATORIUS AB (SE) | 2002-05-10 | — | — | WO | disclosed |
| WO-2001095902-A9 | A COMPOSITION COMPRISING A COMBINATION OF RECEPTOR AGONISTS AND ANTAGONISTS | — | 2002-04-25 | — | — | WO | disclosed |
| WO-2001095902-A1 | A COMPOSITION COMPRISING A COMBINATION OF RECEPTOR AGONISTS AND ANTAGONISTS | RESPIRATORIUS AB (SE) | 2001-12-20 | — | — | WO | disclosed |
| WO-2001095903-A1 | 5-HT3 RECEPTOR ANTAGONISTS FOR TREATMENT OF DISORDERS INVOLVING AIRWAY CONSTRICTION | RESPIRATORIUS AB (SE) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11278530-B2 | Polycyclic amides as muscarinic M1 receptor positive allosteric modulators | CHRM1, CHRM2, CHRM5 | TRPA1 103/4885PARP1 2034/4885CYP11B1 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.